Abstract
Teaser Several genetically-targeted therapies are being developed for ALS. Research is increasingly supportive of a greater incidence of clinically actionable variants in sporadic ALS than previously reported. Salmon et al. outline the need to improve access, and offer genetic testing to all people diagnosed with ALS.
Original language | English |
---|---|
Pages (from-to) | 1207-1210 |
Number of pages | 4 |
Journal | Brain |
Volume | 145 |
Issue number | 4 |
Early online date | 10 Jan 2022 |
DOIs |
|
Publication status | Published - 1 Apr 2022 |
Keywords
- Neurology (clinical)